http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020316102-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_daf40101163479aab17f3930cc393645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d12b35c0dd9adfb167b3b4f383afe93 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-10002 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-10002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate | 2018-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd7d5b914c3972c98a5ae990aac8a1db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f4c23b6bd0aca7b7c7d66f20482f220 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25aa087d21244ad49905180bd29f9c81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_365002bf7137e62a5b5f45f1fcc6eaf2 |
| publicationDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020316102-A1 |
| titleOfInvention | Methods and pharmaceutical composition for the treatment of neurodegenerative disease |
| abstract | In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and postsynaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington's and Alzheimer's mouse models and found that overexpression of PYK2 in these 2 models improves synaptic properties and spine density deficits which is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease. In particular the present invention relates to a method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for PYK2 polypeptide. |
| priorityDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1664.